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Abstract 
Objective 
Elevated LH with normal testosterone (T) suggests compensated dysregulation of the 
gonadal axis. We describe the natural history, risk factors and clinical parameters associated 
with the development of high LH (HLH, LH>9.4 U/L) in ageing men with normal T (T≥10.5 
nmol/L). 
Design, Patients and Measurements 
We conducted a 4.3 year prospective observational study of 3,369 community-dwelling 
European men aged 40-79 years. Participants were classified as: incident (i) HLH (n=101, 
5.2%); persistent (p) HLH (n=128, 6.6%); reverted (r) HLH (n=46, 2.4%); or persistent 
normal LH (pNLH, n=1667, 85.8%). Potential predictors and changes in clinical features 
associated with iHLH and rHLH were analysed using regression models. 
Results 
Age >70 years (OR=4.12[2.07–8.20]), diabetes (OR=2.86[1.42–5.77]), chronic pain 
(OR=2.53[1.34–4.77]), pre-degree education (OR=1.79[1.01–3.20]) and low physical activity 
(PASE≤78, OR=2.37[1.24–4.50]) predicted development of HLH. Younger age (40-49 years, 
OR=8.14[1.35-49.13]) and non-smoking (OR=5.39[1.48–19.65]) predicted recovery from 
HLH. Men with iHLH developed erectile dysfunction, poor health, cardiovascular disease 
(CVD) and cancer more frequently than pNLH men. In pHLH men, co-morbidities, including 
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CVD, developed more frequently, and cognitive and physical function deteriorated more, 
than in pNLH men. Men with HLH developed primary hypogonadism more frequently 
(OR=15.97[5.85–43.60]) than NLH men. Men with rHLH experienced a small rise in BMI. 
Conclusions 
Elevation of LH with normal T is predicted by multiple factors, reverts frequently and is not 
associated with unequivocal evidence of androgen deficiency. High LH is a biomarker for 
deteriorating health in aged men who tend to develop primary hypogonadism.  
 
Introduction 
Ageing is associated with myriad alterations in endocrine functions,1 some of which may 
contribute to a decline in health and quality of later life. Elevated LH with normal testosterone 
(T) is encountered commonly in ageing men2 and may present a diagnostic and therapeutic 
dilemma to the practicing clinician. High LH may signify the onset of dysregulation in the 
hypothalamic-pituitary-testicular (HPT) axis, whereby compensatory increase in luteinising 
hormone (LH) is required to mobilise the Leydig cell steroidogenic reserves to maintain 
normal T production. We have suggested that this may represent a state of ‘compensated’ 
hypogonadism,2 where high LH concentration in the face of normal T (HLH) marks an 
intermediate stage before transitioning towards overt primary hypogonadism (PHG) when 
testicular reserve eventually becomes exhausted. The rate of transition (progression and 
reversal) from normal LH (NLH) to HLH and the factors that influence its development in 
ageing men are important issues that are yet to be explored in prospective studies. Whether 
men with HLH experience symptoms, functional deficits or morbidity, without the 
development of a low T, is unclear. In particular, the proportion of men with HLH who exhibit 
evidence of androgen deficiency is currently unknown. These uncertainties pose important 
questions regarding the clinical significance of abnormally increased LH in ageing men.3 The 
European Male Ageing Study (EMAS)4,5 provides an opportunity to help rectify these 
knowledge gaps through longitudinal observations of unselected men from the general 
population.  
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In this study, we aimed to: 1) identify factors predisposing normal LH men to develop high 
LH and to identify factors, which predict recovery from high LH; 2) determine the clinical 
features associated with high LH; and 3) assess whether men with high LH are at increased 
risk of developing PHG. 
Materials and Methods 
 
Participants and study design 
The study design and recruitment for EMAS have been described previously.4,5 Briefly, an 
age-stratified sample of 3,369 men aged 40–79 (mean±SD: 60±11) years was recruited from 
population registers in eight European centres. Participants completed a postal 
questionnaire and attended a clinic for further assessments. These men were invited to 
participate in the follow-up assessment a median of 4.3 years later (range: 3.0–5.7 years). 
During this period, 168 men died and 407 men were lost to follow-up. Ethical approval for the 
study was obtained in accordance with local requirements in each centre. All participants 
provided written, informed consent. They completed questionnaires both at baseline and at 
follow-up4,5 about smoking, alcohol consumption, and currently treated medical conditions.3 
Anthropometric measurements, Reuben’s physical performance test (PPT), and 
psychomotor processing speed estimation (digit symbol substitution test [DSST]) were 
performed according to standardized methods.4,5 Physical, sexual and psychological function 
was assessed using responses to the Medical Outcome Study (MOS) 36-item Short-Form 
health survey (SF36), the EMAS Sexual Function Questionnaire and the Beck’s Depression 
Inventory.  
 
Hormone measurements 
A single fasting morning (before 1000) blood sample was obtained at baseline and at follow-
up. T was measured by liquid chromatography–tandem mass spectrometry (LC–MS/MS),6 
with paired baseline and follow-up samples analysed simultaneously. LH, FSH and SHBG 
were measured by the E170 platform electrochemiluminescence immunoassay (Roche 
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Diagnostics). The Vermeulen formula was used to calculate free (f) T7 using participant-
specific testosterone, SBHG and albumin values. Intra- and inter-assay coefficients of 
variation (CV) were: T 4.0 and 5.6%; LH 1.9 and 2.7%; FSH 0.9 and 1.9%; and SHBG 1.9 
and 3.2%, respectively. The detection limits for the sex hormones were: T (0.17 nmol/L; 0.05 
ng/mL), LH (0.10 U/L), FSH (0.10 U/L) and SHBG (0.35 nmol/L). Insulin was assayed using 
chemiluminescence (CVs: 3.9% and 5%).  
 
Biochemistry/haematology 
Standardized measurements were undertaken in laboratories in each centre. Insulin 
resistance was calculated using the homeostasis model assessment of insulin resistance 
(HOMA-IR = fasting insulin [U/mL] x fasting glucose [mmol/L]/22.5).8  
 
Categorisation of participants by LH criteria 
Following the criteria described previously,2 participants were categorised according to LH 
and T levels: normal LH (NLH, LH≤9.4 U/L and T≥10.5 nmol/L); high LH (HLH, LH>9.4 U/L 
and T≥10.5 nmol/L). A LH cut-off of 9.4 U/L was chosen because this was the 97.5 centile 
value for men aged 40 to 44 years in the EMAS population.9 Participants were further 
categorised by their change in LH status into one of four groups: incident HLH (iHLH) in 
which men had a normal LH at baseline and an high LH at follow-up; persistent HLH (pHLH) 
in which men had HLH at both baseline and follow-up; reverted HLH (rHLH) in which men 
had HLH at baseline and NLH at follow-up; and pNLH in which men had NLH at both 
baseline and follow-up. 
 
Statistical analysis 
Baseline and follow-up differences between pNLH, iHLH, pHLH and rHLH men in hormone 
levels, anthropometrics, biochemistry, sexual, physical and psychological function, and 
health and lifestyle measures were compared between groups using initially the 
independent-samples t-test or analyses of variance (ANOVA) for continuous variables and χ2 
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tests for categorical variables. Post-hoc analyses were performed using Tukey-Kramer tests 
to allow for multiple pairwise comparisons. Longitudinal within-group differences in 
parameters were compared using the paired t-test for continuous variables and the 
McNemar test for categorical variables.  
Multiple regression models, adjusted for centre as a random effect, were used to account for 
the hierarchical study design (individuals nested within centres). The relationships between 
LH status and putative predictors were assessed using multilevel binary logistic regression 
models, where gonadal status was the outcome, with the pNLH or pHLH group being the 
referent for the analyses of the potential predictors for iHLH or rHLH respectively. Nine 
factors were included as fixed effects: age (40-49 years, 50-59 years, 60-69 years or ≥70 
years), diabetes, BMI (<25 kg/m2, 25-29.9 kg/m2 or ≥30 kg/m2), smoking status (current, ex 
or never), alcohol intake (≥5 days per week or <5 days per week), chronic pain, pre-degree 
education (education obtained to below a university degree level), partner status (living with 
a partner or not) and physical activity (PASE≤78 or >78). The factors chosen were not 
collinear – the variance inflation factors were less than 3.33. 
The relationships between gonadal status and clinical features of high LH were investigated 
using binary logistic regression models when associations between iHLH, pHLH or rHLH 
status with sexual, physical and psychological symptoms or medical conditions were 
assessed, with adjustments for age, comorbidities, BMI, centre, smoking, chronic pain, 
education and physical activity. Linear regression analysis was used when associations 
between iHLH, pHLH or rHLH status with functional ratings were assessed, with adjustments 
for age, comorbidities, BMI, centre, smoking, chronic pain, education and physical activity.  
Results from linear regression models are presented as β-coefficients (for standardized 
variables) with 95% confidence intervals (CI) and results from logistic regression models are 
presented as odds ratios (OR) with 95% CI. All statistical analyses were conducted using 
STATA SE version 13 (StataCorp, College Station, TX). 
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Results 
Natural history of High LH 
Of the 3,369 men recruited into EMAS, 1,942 men made up the analytical sample after 
exclusion of those with known pituitary, testicular or adrenal disease (n=93), men using a 
medication known to affect the HPT-axis (n=217), men who had surgical or medical 
castration (n=2), men who failed to attend for follow-up assessment (n=575), men with 
missing T (n=77) or LH (n=45) data and men with a testosterone level less than 10.5 nmol/L 
at baseline or follow-up (n=418, Figure 1). Men with testosterone levels less than 10.5 
nmol/L in EMAS have been described separately.10,11 Men who died or were lost to follow-up 
were older, in poorer health, had worse physical and cognitive function and were more likely 
to smoke (Supplementary Table 1). This attritional group had also lower fT and higher SHBG 
and LH levels than the analytical sample.   
Of 305 (9.6%) men who had HLH at baseline, 36 died, 50 were lost to follow-up, 19 
developed medical exclusions (e.g. started taking HPT-axis affecting drugs) and 7 had no 
follow-up hormone data. In the remaining 193 men with HLH at baseline with available 
follow-up data, 128 (66.3%) continued to have HLH at follow-up, 46 (23.8%) reverted to 
NLH, 15 (7.8%) developed PHG and 4 (2.1%) developed SHG. The annual incidence of 
PHG among men with HLH at baseline was 1.8 (1.1–3.0)%/year. 
The analytical sample comprised 1,667 (85.8%) men with pNLH, 101 (5.2%) with iHLH, 128 
(6.6%) with pHLH and 46 (2.4%) rHLH men. The incidence (95% confidence interval) of HLH 
over the follow-up period was 5.7 (4.7 - 6.8)% and the annual incidence rate was 1.3 (1.1 - 
1.6)%/year assuming linearity of HLH development. The recovery rate from HLH to NLH was 
26.4 (20.5 - 33.5)% and annual recovery rate was 6.8 (5.1–8.9)%/year.  The prevalence of 
HLH at follow-up was 9.5% (n=229).  
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Characteristics of men who developed high LH 
Age, depression (BDI), fasting glucose and PSA were higher, and cognitive function (DSST) 
and physical activity level (PASE) were lower in iHLH men, at baseline, compared with pNLH 
men (Table 1). Subjective physical function (SF-36 ratings) and objective physical function 
(PPT score) were lower in iHLH men at baseline. At follow-up, these earlier differences 
between the groups persisted, while iHLH men also had lower haemoglobin. The prevalence 
of poor health and chronic illnesses was higher in the iHLH group than in the pNLH group at 
both baseline and follow-up (Table 1).  
Total T levels were similar in iHLH men and pNLH men at baseline and at follow-up (Table 
1). Men with iHLH, compared to pNLH men, had lower fT at baseline (298±94 vs. 327±77 
pmol/L, p<0.001) and at follow-up (282±84 vs. 313 ±76 pmol/L, p<0.001) which may have 
been due to age-related higher SHBG levels at both time-points. As expected by definition, 
LH levels were higher in iHLH men than in pNLH men (Figure 2). 
 
Characteristics of men who recovered from high LH 
Men with rHLH, compared to those with pHLH, were younger, had a lower co-morbidity 
burden and BMI, and had higher sexual function, cognitive processing speed and physical 
function at baseline. These baseline differences persisted at follow-up except for BMI 
(Supplementary table 2). 
Men with rHLH had similar T levels at baseline and at follow-up to men with pHLH 
(Supplementary table 2). Men with rHLH, however, had higher fT levels, compared to men 
with pHLH, at baseline (333±90 vs 269±74 pmol/L, p<0.001) and at follow-up (312±87 vs 
246±74 pmol/L, p<.001). LH levels were lower at baseline and at follow-up in rHLH men 
compared to pHLH men (Figure 2).  
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Predictors of high LH development and recovery 
In men with NLH at baseline, the development of HLH was predicted independently by high 
age (>70 years, OR 4.12 [2.07–8.20], p<0.001), diabetes (OR 2.86 [1.42–5.77], p=0.003), 
chronic pain (OR 2.53 [1.34–4.77], p=0.004), education to a below university degree level 
(OR 1.79 [1.01–3.20], p=0.047) and low physical activity (PASE≤78, OR 2.37 [1.24–4.50], 
p=0.009, Figure 3).  
In men with HLH at baseline, recovery from HLH was predicted independently by younger 
age (40-49 years, OR 8.14 [1.35–49.13], p=0.022 and 50-59 years, OR 3.38 [1.12–10.19], 
p=0.030) and by non-smoker status (OR 5.39 [1.48–19.65], p=0.011, Figure 3).  
 
Symptoms and high LH  
At baseline, NLH men who developed HLH did not report a higher frequency of symptoms 
compared to pNLH men, apart from sadness. Furthermore, they were less likely to report an 
inability to bend (Figure 4). At follow-up, men with incident HLH were more likely to 
experience only a worsening of erectile function, but none of the other 8 symptoms.  
Men with pHLH and pNLH men did not differ in symptom frequency at baseline - pHLH men 
were more likely to develop inability to bend, but none of the other symptoms.  
The prevalence and incidence of symptoms were similar between rHLH and pHLH men at 
baseline or follow-up (Figure 4). 
 
Co-morbidities, Functional Ratings and High LH 
At baseline, men with iHLH were more likely to have diabetes, insulin resistance, lower 
haemoglobin and lower mood (SF-36 mental) than pNLH men (Table 2). At follow-up, men 
with iHLH experienced a greater rise in time taken to walk 50 feet, a greater fall in 
haemoglobin and were more likely to develop poor health, cardiovascular disease and 
cancer than men with pNLH.  
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At baseline, men with pHLH were more likely to have diabetes and cancer, lower cognitive 
processing speed (DSST), higher insulin resistance and lower haemoglobin levels than men 
with pNLH. During follow-up, men with pHLH, compared to men with pNLH, were more likely 
to develop co-morbidity, including CVD, while physical function (PPT-rating) and cognitive 
processing speed worsened more (Table 2).  
 
Progression from High LH to Primary Hypogonadism (PHG) 
Men with HLH at baseline were more likely to develop PHG in both unadjusted analysis (OR 
21.77 [8.76-54.12], p<0.001) and in fully adjusted analysis (OR 15.10 [5.54-41.20], p<0.001) 
than were NLH men. The annual rate of progression from HLH to PHG was 1.8%/year [1.1–
3.0] [total progression rate was 7.8% (4.8-12.4]).  
Men who transitioned from HLH to PHG, compared to pHLH men, had lower T (13.5±2.5 vs. 
19.1±5.5 nmol/L, p<0.001) and fT levels (189±57 vs. 269±74 pmol/L, p<0.001) at baseline, 
while LH (20.4±15.5 vs. 14.4±4.8 U/L, p=0.306) and SHBG levels (68.4±50.1 vs. 61.4±21.5 
nmol/L, p=0.388) were similar. The transition from HLH to PHG was underlined by 
noteworthy declines in both T (-4.8±3.5 nmol/L and -34.2±21.2%) and fT (-58±40 pmol/L and 
-33.3±22.1%), even though T and fT levels were already lower at both baseline and follow-
up compared to other groups. 
Discussion 
In this prospective and longitudinal analysis of 3,369 community-dwelling men, we have 
described, for the first time, the natural history and clinical phenotype of men who develop 
elevated LH (and normal T), have identified risk factors predisposing to the development of 
HLH and documented the likelihood of progression to PHG and recovery from HLH.  
Men who go onto develop HLH, compared to men who do not, experience a greater fall in 
haemoglobin and walking speed with increased risks of developing CVD and cancer. These 
findings, together with the persistently normal mean T of ≥18 nmol/L and a lack of decreased 
libido and morning erections, suggest that the clinical correlates of iHLH are not typical of 
hypogonadism, but rather represent those associated with poor or deteriorating health. This 
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is reinforced further by our findings showing that pHLH men have lower levels of 
haemoglobin and cognitive function (DSST) at baseline, greater worsening of DSST and 
physical functioning over time, and increased comorbidity at baseline (diabetes and cancer) 
and follow-up (CVD).  
We have hypothesised previously that compensated hypogonadism (here referred to as 
HLH) may be a transitional state, which presages the development of overt PHG.2 We show 
now that the development of HLH is predicted independently by age >70 years, diabetes, 
chronic pain, pre-degree education and low physical activity. The longitudinal association 
between high age and iHLH reinforces our previous cross-sectional results.2 This 
association, together with the novel identification of diabetes, pain and physical activity as 
factors that predispose to the development of HLH, suggest that HLH can be regarded as a 
feature of functional ageing. The possible link between socioeconomic factors (education to 
a less than university degree level) and the development of HLH presents a fresh 
perspective on the predisposition to adverse outcomes of endocrine ageing. It is recognised 
that people with better educational attainment are healthier and live longer12 – it may be that 
Leydig cell functional reserve plays a mediating role in this relationship. Interestingly, obesity 
is not a predictor of HLH, yet the occurrence of HLH appears to be predicted by diabetes. In 
this respect, HLH is more closely linked to PHG11 than to SHG which is related to obesity 
and not to age or chronic illness.10 This highlights the different underlying pathophysiological 
mechanisms contributing to the decline in T in older men as well as their distinct clinical 
implications.  
It follows that a vicious circle may exist for men with HLH – factors associated with 
accelerated functional ageing (diabetes, chronic pain, physical inactivity) predispose to HLH 
development and HLH, in turn, predisposes to further functional decline (decrease in 
haemoglobin, physical function and cognitive function as well as development of CVD).  
With a baseline prevalence of HLH in EMAS of 9.4%,2 an incidence rate of 1.3%/year and 
recovery rate of 6.8%/year, HLH appears to be a relatively common but reversible condition 
in the general population.  Recovery from HLH was associated with younger age and being 
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a non-smoker. It is plausible, that, as compared to pHLH men, the younger rHLH men might 
have a higher reserve of testicular steroidogenic function or Leydig cell population, which 
allowed them to compensate for potential insults to Leydig cells due to disease. Less likely is 
the possibility that younger and healthier men had greater LH pulsatility (vide infra) 
increasing their chance of being classified as HLH at baseline due to blood taking during an 
LH pulse. The observation that non-smoking is a predictor for the recovery from HLH is in 
agreement with our baseline cross-sectional findings showing that smoking status is related 
to HLH.2 The higher SHBG levels observed in smokers might explain this finding,13 although 
the exact mechanism, remains unclear. Except for minor changes in BMI, none of the 
androgen-sensitive endpoints or medical conditions assessed within our study were 
associated or changed with rHLH. This supports the view that HLH is not a hypogonadal 
condition although a significant proportion of HLH men will go on to develop PHG within the 
ensuing 5 years.   
The HPT axis is regulated tightly in older as in young men14 and elevated LH is highly 
responsive to age-related deficits in Leydig cell mass15 and function.16 Impaired testicular 
response to LH can be caused by exposure to cytokines,17,18 arising from chronic low grade 
inflammation,19 which is common in ageing.20 Testicular failure with elevated gonadotropins 
is also associated with chronic diseases of ageing including cancer,21 diabetes,22 renal and 
liver failure and COPD.23 In addition, elevated LH, independent of testicular failure, has been 
associated with increased all-cause and cancer-specific mortality.24 Elevated LH can be 
therefore considered a biomarker of poor health and subclinical chronic diseases. 
Accordingly, iHLH is predicted by the presence of diabetes, and iHLH men are at risk of 
developing CVD and cancer. 
 
Strengths and limitations 
This prospective study provided an opportunity to investigate the temporal relationships 
between the earliest ageing-related changes in HPT-axis function and their clinical 
correlates. The strengths of the study include the longitudinal follow-up of a large number of 
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unselected participants from the general population and the breadth of the phenotypic data 
collected by standardised validated methods between the phases of the study. T was 
measured by LC–MS/MS with paired baseline and follow-up samples analysed 
simultaneously. Limitations in EMAS have been described previously.4,5 The follow-up period 
of 4.3 (range: 3.0–5.7) years may be a relatively short time in which to capture more 
protracted changes in signs and symptoms of hypogonadism. A relatively small number of 
men developed HLH - this is unavoidable given the relatively low incidence of the condition 
which has not been previously described. However, the ability to identify significant and 
consistent associations (albeit with wide confidence intervals) despite the relatively small 
numbers of cases supports the validity of our findings and conclusions. At both study 
phases, a single LH and T measurement only was available to categorise gonadal status. 
This may have introduced errors in classification although the consistency of higher LH 
between baseline and follow-up and the parallel changes in FSH add confidence to our 
results. Multiple blood sample collection is impractical in large epidemiological surveys25,26 
such as ours.  Several studies have confirmed that T levels within the same individual do not 
fluctuate significantly when measured serially over several months.27-30 Similarly, the diurnal 
variation in LH levels is markedly less prominent, if not absent, in older men.31 In our 
analytical sample, the co-efficients of correlation between baseline and follow-up T and LH 
levels were 0.72 (p<0.001) and 0.80 (p<0.001) respectively. It is unlikely, therefore, that 
single hormone determination in the present study would have introduced substantial 
misclassification of gonadal status. The fact that the vast majority of EMAS participants had 
a normal LH at baseline and at follow-up and the parallel changes in FSH attest to this.  
 
Conclusions and clinical implications 
Age greater than 70 years, diabetes, chronic pain, pre-degree education and low physical 
activity predispose men to the development of high LH, which may be reversible in younger 
men. High LH, (with normal T), can be regarded as a sensitive biomarker of poor health and 
a risk factor for developing PHG. Incident HLH is not associated with unequivocal evidence 
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of androgen deficiency. Even if HLH persists for several years, the emergent physical and 
cognitive impairments are not typical features of hypogonadism, but rather reflect 
deteriorating health during ageing.  
In clinical practice, men with elevated LH and normal T should be followed up for their 
general as well as endocrine reproductive health, but there is no indication for T replacement 
therapy unless T falls into the hypogonadal range and more features of androgen deficiency 
appear (i.e. progression to PHG).  
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Figure Legends 
 
Fig. 1. Flowchart of Participants  
pNLH, persistent Normal LH; iHLH, incident High LH; pHLH, persistent High LH; and rHLH, 
recovery from High LH. 
 
Fig. 2. Sex hormone levels and LH status at baseline and follow-up for men with persistent 
Normal LH (pNLH), incident HLH (iHLH), persistent HLH (pHLH), and recovery from HLH 
(rHLH) 
Baseline and follow-up hormone concentrations are expressed as means (upper limits of 
bars) and as standard errors of the means (upper limits of the error bars). Data in the groups 
were compared, and p-values were generated, using analyses of variance (ANOVA) and 
Tukey-Kramer post-hoc analyses to permit correction for multiple pairwise comparisons.  
Solid black bars at follow-up with the letter ‘a’ indicate that follow-up hormone levels in this 
group differed significantly from baseline hormone levels in the same group when analysed 
using the paired t-test.  
Lines and brackets with stars above bars indicate statistically significant differences between 
the two groups (p<0.05). The horizontal dotted lines represent values above or below which 
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are considered abnormal (10.5 nmol/L for total testosterone, 220 pmol/L for calculated free 
testosterone, and 9.4 U/L for luteinising hormone). 
 
Fig. 3. Potential Risk Factors for development of, and recovery from, High LH 
Data are expressed as odds ratio (symbol) ±95% confidence interval (error bars). In the left 
panels, odds ratios and p-values were determined using single independent variables and 
binary logistic regression analyses (unadjusted/univariate). In the right panels, odds ratios 
and p-values were determined using multiple binary logistic regression analysis including all 
the potential risk factors listed in the same model.  
*, p<0.05; **, p<0.01; ***, p<0.001 
 
Fig. 4. Relationships between Symptoms and High LH. 
Data are expressed as odds ratios (▲) ±95% confidence intervals (error bars). Odds ratios 
and p-values were determined using regression analyses. Data from the incident high LH 
(iHLH) and persistent high LH (pHLH) groups were compared to those from the referent 
group of persistent normal LH (pNLH). Recovery from high LH (rHLH) data were compared 
to those of pHLH men. The statistical analysis was performed with adjustment for age, co-
morbidity, body mass index, centre, chronic pain, education, smoking, and physical activity. 
The left panels show the odds ratios for the prevalence of symptoms at baseline. The right 
panels show the odds ratios for the development/worsening of symptoms. 
*, p<0.05; **, p<0.01.  
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Table 1. Baseline and Follow-Up Characteristics of Men with Persistently Normal LH and those with Incident High LH  
 Baseline Follow-Up 
Parameter pNLH iHLH P
a
 pNLH iHLH P
b
 
N 1,667 101  1,667 101  
Age, years 57.2 ±10.1 63.9 ±10.9 <.001 61.6 ±10.1*** 68.2 ±10.9*** <.001 
Pre-degree Education
c
, n (%) --- --- --- 1132 (69.2) 79 (81.4) 0.039 
Living with partner, n (%) --- --- --- 1325 (85.0) 77 (81.9) 0.420 
Smoking, n (%) 333 (20.2) 23 (22.8) 0.521 285 (17.7)*** 22 (23.4) 0.093 
Frequent Alcohol, n (%) 415 (25.0) 22 (21.8) 0.758 519 (35.9)*** 25 (27.2) 0.312 
Chronic widespread pain, n (%) 122 (7.6) 14 (14.4) 0.145 --- --- --- 
Poor health, n (%) 308 (18.6) 31 (31.0) <.001 353 (21.9)*** 37 (38.1) <.001 
≥1 illness, n (%) 593 (35.6) 50 (49.5) <.001 379 (50.2)*** 72 (71.3)*** <.001 
≥2 illnesses, n (%) 216 (16.7) 22 (30.1) <.001 438 (34.5)*** 43 (59.7)*** <.001 
Diabetes, n (%) 73 (4.4) 15 (15.0) <.001 91 (5.6)*** 16 (16.5) <001 
CVD, n (%) 466 (28.4) 37 (37.0) 0.001 588 (37.6)*** 56 (57.7)*** <.001 
Cancer, n (%) 59 (3.5) 4 (4.0) <.001 114 (7.2)*** 12 (13.2)** <.001 
Prostate disease, n (%) 135 (8.2) 5 (5.0) 0.003 156 (9.7)* 12 (12.4)* 0.684 
Overall Sexual Function 22.5 ±6.4 20.2 ±7.2 0.002 21.7 ±6.7*** 18.1 ±7.6* <.001 
SF-36 physical 51.5 ±7.3 49.7 ±8.4 0.031 50.9 ±8.0** 48.9 ±8.8 0.044 
Beck’s Depression Inventory 6.1 ±5.9 8.0 ±6.8 0.003 6.0 ±6.4 7.7 ±6.4 0.003 
SF-36 mental 52.1 ±8.7 50.3 ±8.4 0.016 52.0 ±9.2 50.4 ±9.0 0.044 
DSST 29.5 ±8.1 25.3 ±8.6 <.001 28.7 ±8.6*** 23.3 ±9.0** <.001 
PASE score 211.4 ±86.4 183.5 ±95.1 0.005 186.9 ±92.7*** 165.4 ±91.8 0.020 
50-ft walk, sec 13.0 ±2.8 13.5 ±2.8 0.040 13.6 ±2.8*** 14.8 ±3.2*** <.001 
PPT rating 24.4 ±2.4 23.8 ±2.7 0.035 24.0 ±2.4*** 23.0 ±2.6*** 0.001 
BMI, kg/m
2
 27.2 ±3.8 27.2 ±4.1 0.935 27.3 ±3.9** 27.5 ±4.7 0.822 
FPG, mmol/L 5.4 ±0.9 5.9 ±1.5 0.006 5.4 ±1.3** 5.7 ±1.4 0.034 
HOMA-IR 2.7 ±2.6 3.6 ±7.5 0.647 2.7 ±2.1* 2.7 ±2.3* 0.590 
PSA, ng/ml 1.5 ±2.1 2.2 ±3.6 0.003 2.0 ±5.2*** 2.7 ±4.3 0.043 
Hb, g/L 150.8 ±10.4 148.5 ±11.2 0.053 150.7 ±10.8 143.3 ±16.9* <.001 
Total T, nmol/L 18.4 ±5.4 18.0 ±5.1 0.611 18.1 ±5.4** 18.2 ±5.6 0.818 
Free T, pmol/L 326.7 ±77.4 298.4 ±93.7 <.001 312.6 ±76.0*** 281.5 ±84.2* <.001 
SHBG, nmol/L 42.9 ±17.3 48.3 ±17.0 <.001 45.4 ±18.7*** 54.8 ±21.7*** <.001 
LH, U/L 5.0 ±1.7 7.4 ±1.4 <.001 5.0 ±1.8 11.5 ±2.4*** <.001 
FSH, U/L 6.1 ±3.4 11.2 ±6.2 <.001 6.2 ±3.5  14.8 ±8.4*** <.001 
Data are expressed as mean ±standard deviation for continuous variables or as number (percentage) for binary categorical variables. 
Abbreviations: NLH, Normal Luteinising Hormone; HLH, High Luteinising Hormone; CVD, CardioVascular Disease; SF-36, Short-Form 36 Questionnaire; DSST, Digital Symbol Substitution Test; 
PASE, Physical Activity Scale for the Elderly; PPT, Physical Performance Test; BMI, Body Mass Index; FPG, Fasting Plasma Glucose concentration; HOMA-IR, HOmeostatic Model of Insulin 
Resistance; PSA, Prostate Specific Antigen concentration; Hb, Haemoglobin; T, serum Testosterone concentration; SHBG, Sex Hormone Binding Globulin concentration; LH, Luteinising Hormone 
concentration; FSH, Follicular Stimulating Hormone Concentration 
a. P values were calculated using baseline parameters and either the independent-samples t-test for continuous variables or chi-squared analyses for categorical variables. 
b. P values were calculated using follow-up parameters and either the independent-samples t-test for continuous variables or chi-squared analyses for categorical variables. 
c. Educated to less than a degree level 
*, **, *** Data differ significantly (p<0.05, p<0.01 and p<0.001 respectively) from baseline values within the same group when analysed using paired t-tests (for continuous variables) or the McNemar 
test (for categorical variables). 
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Table 2. Co-morbidities, Functional Ratings and Elevated Luteinising Hormone 
 Incident HLH (n=101) Persistent HLH (n=128) Recovery from HLH (n=46) 
Parameter Baseline Change
a
 Baseline Change
a
 Baseline Change
a
 
Poor health, n (%) 1.29 (0.76, 2.18) 1.98 (1.01, 3.90)* 1.39 (0.86, 2.22) 1.60 (0.84, 3.03) 0.74 (0.26, 2.09) 0.56 (0.13, 2.37) 
≥1 illness, n (%)  1.10 (0.68, 1.78) 1.75 (0.92, 3.31) 1.76 (1.12, 2.76)* 2.02 (1.03, 3.98)* 0.49 (0.21, 1.14) 0.52 (0.14, 1.85) 
≥2 illnesses, n (%)  0.99 (0.52, 1.86) 1.85 (0.84, 4.06) 1.85 (1.05, 3.26)* 2.09 (0.94, 4.66) 0.86 (0.30, 2.48) 0.78 (0.07, 8.42) 
Diabetes, n (%) 2.62 (1.34, 5.14)***
 
 0.35 (0.05, 2.73) 2.13 (1.12, 4.08)* 0.36 (0.05, 2.81) 0.36 (0.07, 1.94) 12.75 (0.49, 332.44) 
CVD, n (%) 0.89 (0.54, 1.46) 2.09 (1.12, 3.90)* 1.37 (0.88, 2.12) 2.58 (1.33, 5.00)** 0.80 (0.33, 1.95) 0.92 (0.29, 2.87) 
Cancer, n (%) 0.67 (0.20, 2.25) 2.77 (1.29, 5.97)* 2.06 (1.05, 4.05)* 0.88 (0.33, 2.34) 1.28 (0.34, 4.76) 1.74 (0.33, 9.22) 
Prostate disease, n (%) 0.27 (0.09, 0.77)* 1.18 (0.53, 2.66) 1.21 (0.70, 2.09) 0.34 (0.10, 1.14) 0.52 (0.13, 2.09) 5.54 (0.70, 44.16) 
Overall Sexual Function -0.03 (-0.08, 0.02) -0.02 (-0.08, 0.04) -0.02 (-0.07, 0.02) -0.00 (-0.06, 0.06) 0.05 (-0.11, 0.21) -0.01 (-0.24, 0.23) 
SF-36 physical 0.01 (-0.03, 0.06) -0.03 (-0.08, 0.02) -0.00 (-0.05, 0.04) -0.05 (-0.10, 0.01) -0.04 (-0.19, 0.12) -0.02 (-0.19, 0.16) 
Beck’s Depression 
Inventory 
0.03 (-0.01, 0.08) 0.03 (-0.02, 0.09) 0.04 (-0.01, 0.09) -0.02 (-0.07, 0.04) -0.09 (-0.26, 0.07) 0.11 (-0.06, 0.28) 
SF-36 mental -0.05 (-0.10, -0.00)* -0.00 (-0.05, 0.05) -0.01 (-0.06, 0.04) -0.02 (-0.08, 0.03) 0.03 (-0.14, 0.19) 0.02 (-0.15, 0.20) 
DSST -0.03 (-0.07, 0.01) -0.02 (-0.07, 0.03) -0.07 (-0.11, -0.02)** -0.05 (-0.10, -0.00)* 0.08 (-0.06, 0.21) 0.10 (-0.07, 0.26) 
PASE score -0.03 (-0.08, 0.01) 0.02 (-0.03, 0.08) -0.04 (-0.09, 0.01) -0.04 (-0.10, 0.01) 0.00 (-0.15, 0.15) 0.04 (-0.14, 0.23) 
50-ft walk, seconds -0.01 (-0.06, 0.03) 0.05 (0.01, 0.10)* -0.00 (-0.05, 0.04) 0.03 (-0.01, 0.08) -0.15 (-0.30, 0.00) 0.10 (-0.06, 0.27) 
PPT rating 0.01 (-0.04, 0.05) -0.01 (-0.06, 0.04) 0.00 (-0.04, 0.05) -0.09 (-0.14, -0.04)** -0.05 (-0.11, 0.20) 0.03 (-0.14, 0.20) 
BMI, kg/m
2
 -0.01 (-0.05, 0.04) -0.01 (-0.06, 0.04) -0.04 (-0.09, 0.01) 0.01 (-0.04, 0.06) -0.10 (-0.26, 0.06) 0.21 (0.05, 0.36)* 
HOMA-IR 0.07 (0.02, 0.11)** -0.02 (-0.07, 0.04) 0.09 (0.04, 0.14)*** 0.01 (-0.04, 0.07) -0.04 (-0.20, 0.12) 0.11 (-0.07, 0.29) 
Hb, g/L -0.05 (-0.10, -0.00)* -0.06 (-0.11, -0.01)* -0.10 (-0.15, -0.05)*** 0.04 (-0.01, 0.10) 0.10 (-0.07, 0.26) -0.15 (-0.33, 0.03) 
Data are expressed as odds ratio (95% confidence interval) for binary categorical variables or as regression co-efficient (95% confidence interval) for continuous variables.  
Data from men with incident or persistent HLH were compared to those from men with persistently normal LH levels. Data from men with recovery from HLH were compared to those from men with 
persistent HLH. All relationships are adjusted for age, co-morbidity, body mass index, centre, chronic pain, education, smoking, and physical activity. 
Abbreviations: HLH, High Luteinising Hormone; CVD, CardioVascular Disease; SF-36, Short-Form 36 Questionnaire; DSST, Digital Symbol Substitution Test; PASE, Physical Activity Scale for the 
Elderly; PPT, Physical Performance Test; BMI, Body Mass Index; HOMA-IR, HOmeostatic Model of Insulin Resistance; Hb, Haemoglobin. 
a. incidence of co-morbidity or percentage change from baseline for functional ratings 
*, p<0.05; **, p<0.01; ***, p<0.001 
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